← Back

BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc. is a biotechnology company operating in Israel and the United States through two segments: Products and CDMO Services. It develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. The company researches, develops, manufactures, markets, and sells science-based health and wellness nutraceutical solutions, including dietary supplements, functional foods and beverages, as well as health, pharmaceutical, and cosmeceutical solutions. It also provides contract development and manufacturing services, offers VINIA (a red grape cell dietary supplement containing the matrix of polyphenols found in red wine), and has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.

Price · split & dividend adjusted
News & notes moving BHST
BHST▲

BioHarvest Sciences Registers for Dual Listing on Tel Aviv Stock Exchange

BioHarvest Sciences Inc., a leader in Botanical Synthesis technology, announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, already listed on the Nasdaq Capital Market, will register all outstanding and potential future shares for the TASE listing, including 22,667,842 outstanding common shares, up to 4,516,021 shares reserved for its equity incentive plan, and 610,742 shares issuable upon exercise of warrants. CEO Dr. Zaki Rakib said the dual listing is a natural step for the Israeli-founded company to broaden access to its shares and strengthen ties with the Israeli investment community. The shares will trade under the symbol BHST in English and "בהסט" in Hebrew, and all future EDGAR filings will also be submitted through the MAGNA Disclosure System.
BHST ▲
Newsfile Corp.·15dRead more →
BHST▼

BioHarvest Sciences secures first CDMO fragrance deal, cuts 2026 revenue guidance

BioHarvest Sciences secured its first-ever CDMO manufacturing and supply agreement for a rare premium fragrance, a milestone reached significantly ahead of schedule. The company revised its total 2026 revenue guidance downward to $37 million to $40 million from the previous $42 million to $48 million range, citing deliberate spending discipline in its direct-to-consumer business amid double-digit media inflation on platforms like Meta. Management now targets consolidated EBITDA breakeven in 2027 and projects the new fragrance agreement will generate $20 million to $30 million in revenue during the 2027-2028 time frame, with limited production starting in the first half of 2027. The company is shifting its strategy from proving the breadth of its Botanical Synthesis applications to selectively converting high-value opportunities into recurring manufacturing revenue and royalties, while reallocating capital from the D2C segment toward manufacturing capacity build-out and the growing CDMO division. BioHarvest also plans to launch single-dose VINIA Daily Chews in September 2026 and is developing a long-term licensing model for high-volume products like sweeteners, where partners build their own facilities and the company collects royalties.
BHST ▼
Yahoo Finance·38dRead more →
BHST▼

BioHarvest Sciences Q2 GAAP EPS misses estimates by $0.05, revenue misses by $0.61M

BioHarvest Sciences reported second-quarter results that fell short of analyst expectations. The company posted a GAAP loss of $0.17 per share, missing estimates by $0.05. Revenue came in at $8.84 million, a 3.8% increase year-over-year, but missed the consensus forecast by $0.61 million.
BHST ▼
Seeking Alpha·38dRead more →
© 2026 MarketDXAsset